E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma (NCT01133977), a randomized phase 1, phase 2 study. The primary outcome is Dose Limiting Toxicity (DLT) of Lenvatinib Administered in Combination With Dacarbazine (for Phase 1b).

2. Clinical Question

The study concerned participants with stage IV melanoma receiving first-line therapy. Its two phases addressed related but distinct questions: the Phase Ib portion sought to characterize safety and tolerability and define a maximum tolerated dose for lenvatinib combined with dacarbazine; the Phase II portion was intended to evaluate safety and tolerability of the combination against dacarbazine alone. A preliminary efficacy assessment in Phase II was a secondary objective.

These objectives should not be collapsed into a single efficacy question. The primary endpoint listed for the record belongs to dose finding in Phase Ib, while progression-free survival was a secondary outcome for Phase II. Numerical results for that endpoint and for progression-free survival are not reported in the registry record.

3. Trial Design

NCT01133977 is described as an open-label, multicenter, randomized, parallel Phase Ib/II study. The overall enrollment recorded was 97. The study status is completed; the recorded start is 2010-04 and primary completion is 2014-06. These dates describe the registry record and do not, by themselves, explain the duration of follow-up for any endpoint.

The design had a dose-finding component followed by a randomized comparative component. In Phase Ib, lenvatinib was administered once daily at 16 mg, 20 mg or 22 mg with dacarbazine. The stated purpose was to assess safety and tolerability and determine the maximum tolerated dose. The Phase II combination arm used lenvatinib at the maximum tolerated dose determined during Phase Ib, together with dacarbazine. The comparator arm received dacarbazine.

The registry identifies random allocation but does not report the allocation ratio, the sequence-generation method, or details about allocation concealment. None of those details should be inferred from the word “randomized.” The trial was unmasked, so participants and investigators were not blinded to treatment assignment according to the recorded masking status. The record does not describe additional procedures intended to limit the effect of that knowledge on outcome assessment.

Safety and tolerability were central objectives in both phases. The Phase Ib primary endpoint was participants with a dose-limiting toxicity during the first cycle. Phase II had a stated comparative safety and tolerability objective, with progression-free survival as a secondary outcome and a preliminary efficacy assessment also described. Numerical outcome results for these objectives are not reported in the registry record presented for analysis. The record also does not state a sample-size justification, the planned duration of follow-up, or whether interim analyses were planned.

The overall enrollment should not be treated as the size of either Phase II treatment group. Safety figures are listed separately by dose cohort and Phase II arm, but the registry description does not make the allocation process or analysis populations fully explicit. The recorded study design therefore supports a description of the intended structure, but not a reconstruction of all operational details or a complete assessment of comparative efficacy.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Safety Analysis Set: All participants enrolled in the Phase 1b portion of this study, except for those who (i) dropped out of the study prior to receiving any study drug, or (ii) were without any safety assessment following the first dose of study drug.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: A total of 40 participants were randomized in Dacarbazine (Phase 2) arm but only 39 participants received study drug and were included in the safety analysis set.

6. Primary Endpoint

The registry lists the primary outcome as Dose Limiting Toxicity (DLT) of Lenvatinib Administered in Combination With Dacarbazine (for Phase 1b), measured over From Day 1 through 21 days (one cycle).

The listed primary endpoint is the number of Phase Ib participants with a dose-limiting toxicity while receiving lenvatinib with dacarbazine. The registry defines a dose-limiting toxicity as a clinically significant adverse event occurring at or before 21 days after study treatment began and judged by the investigator to be possibly or probably related to study treatment. The listed timeframe is Day 1 through 21 days, described as one cycle.

This endpoint is used in dose-finding because it focuses attention on treatment-related toxicities arising in a prespecified early period. In general, early toxicity information can help investigators judge whether a dose merits further study and can inform selection of a dose for a later trial phase. That is the general role of this kind of endpoint; it does not establish that any particular dose is safe or suitable for an individual.

The endpoint is a count of participants meeting the toxicity definition, not a measure of tumor response or survival. The record’s description also leaves an important element of interpretation to investigator judgment: whether an event was clinically significant and possibly or probably related to treatment. The record does not provide the numerical dose-limiting toxicity result by cohort, nor does it report the dose-selection analysis. Accordingly, the endpoint definition can be described, but the result for the primary endpoint cannot be assessed from the registry record.

Progression-free survival is identified separately as a Phase II secondary outcome. It should not be substituted for the Phase Ib primary endpoint when interpreting the study’s stated primary result.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Interpreting a clinical trial requires separating its design, endpoint definitions, analysis population, and posted results. The registry describes randomization, an open-label parallel structure, and two phases, but these labels do not reveal every methodological detail. Randomization generally aims to make treatment groups comparable with respect to both measured and unmeasured factors at allocation. It does not guarantee that groups will be identical, particularly when group sizes are modest, and it does not remove the need to report how randomization was carried out.

What does the dose-finding endpoint capture?

The primary endpoint concerns whether a Phase Ib participant experienced a dose-limiting toxicity in the initial treatment period. It is a binary participant-level outcome: a participant either meets the specified DLT definition or does not. The definition in the registry combines timing, clinical significance, and investigator-assessed relationship to study treatment. This makes the endpoint more specific than a count of all adverse events, but it also means classification depends partly on clinical judgment. The registry does not report the number of participants meeting this endpoint at each dose, or the procedure used to select the maximum tolerated dose.

In general, dose-finding studies use toxicity observations to guide decisions about doses for later research. A maximum tolerated dose is a study-specific result under the protocol’s definitions and observed participants; it is not a guarantee that the same tolerability will occur in other populations or settings. Since the dose-selection result is not reported in the registry record, the Phase II dose cannot be independently connected to the observed Phase Ib DLT pattern from the information available.

How should randomized comparisons be read?

Phase II is described as randomized, with lenvatinib plus dacarbazine compared with dacarbazine alone. In general, a randomized comparison is designed to estimate differences between assigned groups while reducing confounding at allocation. The validity and interpretation of such an estimate still depend on the analysis population, adherence, follow-up, outcome measurement, and missing-data handling. The registry record does not report enough detail to assess all of these features.

The study is open-label. In general, knowledge of treatment assignment can affect behaviors, co-interventions, reporting of subjective symptoms, or clinical assessment. This is not proof that any recorded outcome was biased. It is a design feature that readers should consider, especially for outcomes involving judgment. The DLT definition includes investigator assessment of relatedness, while the registry does not state whether outcome adjudication was independent or masked.

What do counts and percentages tell the reader?

A count reports how many participants had an event. The accompanying group size provides context, but a count alone does not express uncertainty or establish a comparative effect. The posted serious-event counts include 2 of 3, 4 of 7, and 2 of 6 in the Phase Ib dose cohorts, as well as 16 of 42 and 1 of 39 in the Phase II groups. These values should remain separated by phase and treatment group. The different Phase Ib cohorts are not additional randomized arms in the Phase II comparison.

In general, proportions can be unstable when based on small groups: a small change in the number of participants with an event can change the apparent proportion substantially. Confidence intervals can make this uncertainty visible. The registry record does not report confidence intervals for these safety counts, and no new interval or comparative estimate should be inferred from them. The listed serious adverse event terms each carry 33.3%, but without clear group-specific denominators and definitions in the record, those percentages cannot be translated into treatment-specific event risks.

Over-dispersion is a general statistical issue in settings where observed variability exceeds what a simple model assumes. It can make model-based uncertainty too narrow if ignored. The posted safety information is count-based and does not identify a model or estimate of over-dispersion, so there is no basis to describe an adjusted analysis for this trial. More broadly, a statistical model should be interpreted only with its outcome definition, assumptions, and analysis population in view.

What can a planning illustration establish?

The registry-linked planning assumptions describe a two-sided significance level of 0.05, equal allocation, a normal approximation, and an effect defined as a stated fraction of the observed effect. For time-to-event outcomes, the stated convention is a total number of events; for other outcomes, the convention is participants per arm. These are planning assumptions, not evidence that the original trial used that approach, and the record does not report the trial’s own sample-size justification.

In general, a sample-size calculation estimates the amount of information a future study might need under specified assumptions. It does not measure the probability that a completed trial’s result is true, and it is not “observed power.” Planning illustrations based on an observed effect can be particularly sensitive to uncertainty in that observed effect. The calculation should be treated as a hypothetical planning aid, not as a feature of the original trial protocol. The record does not report enough information to assess whether its original enrollment was adequate for a particular treatment effect.

The same caution applies to statistical significance. A p-value, if reported, would describe compatibility between the observed data and a specified null model under assumptions; it would not measure clinical importance or the probability that a treatment works. No p-value or comparative estimate for the primary endpoint is reported in the registry record. The endpoint result cannot be reconstructed from the safety event counts because serious adverse events and dose-limiting toxicities are separately defined outcomes.

Why are endpoint and analysis population details essential?

An analysis population specifies which participants contribute to an outcome analysis and under what rules. For Phase Ib, the record names a safety analysis set and excludes participants who dropped out before receiving any study drug or had no safety assessment following the first dose. The record does not provide an equivalent definition for the Phase II analysis population. In general, different analysis populations can answer different questions, so a label such as safety analysis set should not be assumed to mean an intention-to-treat analysis.

Missing-data methods also affect interpretation. If participants lack endpoint assessments, their inclusion or exclusion can influence estimates, particularly when missingness is related to health status or treatment experience. The registry does not report how missing endpoint data were handled, how many participants lacked data for each outcome, or whether sensitivity analyses were conducted. These omissions limit assessment of possible bias and precision. They do not establish that missing data occurred; they mean the handling is not reported in the registry record.

Finally, multiplicity refers generally to the statistical challenge created by evaluating multiple outcomes, time points, groups, or analyses. If many comparisons are made, the chance of a nominally notable result can increase unless the analysis plan addresses that issue. The record lists multiple outcomes and safety measures but does not report a multiplicity procedure or detailed statistical analysis plan. It is therefore not possible to determine which analyses, if any, were adjusted or designated as confirmatory beyond the objectives explicitly described.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists a Phase Ib primary endpoint and describes Phase II safety and tolerability as a primary objective, with progression-free survival as a secondary outcome. It does not report a detailed statistical analysis plan specifying the hierarchy of outcomes, comparison time points, or treatment of multiple analyses. A multiplicity adjustment or other control procedure is not reported in the registry record. No inference should be made that one was or was not used in the trial beyond what the record states.

Missing-data handling is also not reported. The record does not describe the number of participants with missing outcome assessments, the rules used to include or exclude them from Phase II outcome analyses, or any sensitivity analyses. The Phase Ib safety analysis set is defined as enrolled participants except those who left before receiving study drug or had no safety assessment after the first dose. This definition should not be assumed to apply to Phase II or to progression-free survival.

In general, the choice of analysis population and the treatment of missing observations can affect an estimate. An analysis restricted to participants with available data may differ from an analysis that retains participants according to randomized assignment, especially if missingness is related to treatment or outcome. The record does not provide enough information to assess this possibility. Nor does it report whether interim analyses were planned or performed. These are limits on interpretation of the registry information, not evidence that a particular analysis or missing-data problem occurred.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: cardiac failure congestive (33.3%), ileus (33.3%), asthenia (33.3%), fatigue (33.3%), white blood cell count increased (33.3%).

The serious adverse event figures are counts within the listed safety groups. The record lists 2 of 3 participants in the 16 mg lenvatinib plus dacarbazine Phase Ib cohort, 4 of 7 in the 20 mg cohort, and 2 of 6 in the 22 mg cohort as having serious adverse events. For Phase II, it lists 16 of 42 in the 20 mg lenvatinib plus dacarbazine group and 1 of 39 in the dacarbazine group. These are descriptive figures, not an adjusted comparison or a causal estimate.

Phase Ib and Phase II groups have different roles in the study. The Phase Ib cohorts were part of dose finding; the Phase II groups form the stated randomized comparison. Combining those groups would blur the distinction between the phases. The record does not report deaths for these groups; the death values are not reported in the registry record.

The serious adverse event terms listed include Cardiac Failure Congestive, Ileus, Asthenia, Fatigue, White Blood Cell Count Increased, and Dehydration, each shown with 33.3%. The record does not make the denominator or treatment-group mapping for these term percentages clear enough to interpret them as group-specific risks. A serious event count also does not mean that every event was caused by study treatment. The listed figures describe what was recorded, not what an individual participant should expect.

12. What the Result Does, and Does Not, Mean

The record establishes that this was a randomized, open-label Phase Ib/II study of lenvatinib with dacarbazine and dacarbazine alone in first-line treatment of stage IV melanoma. It sets out a dose-finding objective in Phase Ib and comparative safety and tolerability objectives in Phase II. It also identifies progression-free survival as a Phase II secondary outcome. These statements describe the study’s purpose and structure; they are not results showing that a treatment was effective or ineffective.

The posted serious adverse event counts describe events recorded within the listed groups. They can help readers understand what safety information is present in the registry, but the counts alone do not account for uncertainty, potential differences between participants, exposure duration, or outcome ascertainment. The Phase Ib dose cohorts should not be interpreted as randomized comparisons against each other. The Phase II counts should not be treated as proof of a treatment effect without a comparative estimate and its uncertainty.

The Phase Ib DLT result is not reported in the registry record. The Phase II comparative efficacy result, including the progression-free survival result, is also not reported. The maximum tolerated dose determination is not reported as an outcome. Consequently, the available information cannot establish how the dose-finding objective was resolved or what the comparative outcome estimates were.

In general, absence of a reported result is not evidence that an outcome did not occur, and it is not evidence of no difference between groups. Likewise, a recorded adverse event is not automatically attributable to treatment. Interpretation requires the endpoint definition, analysis population, follow-up, and statistical uncertainty, several of which are not reported for these outcomes.

The registry information therefore supports a description of the planned questions, trial structure, and selected safety counts. It does not support a conclusion about whether lenvatinib plus dacarbazine improved outcomes, whether it had a particular comparative risk, or whether the study ruled out meaningful effects. Those judgments require outcome estimates and methods that are not reported in the registry record.

13. Why This Trial Matters Statistically

This trial is statistically notable for combining a dose-finding phase with a randomized comparative phase. The two parts answer different kinds of questions. Phase Ib focused on identifying a tolerable dose using an early toxicity endpoint, while Phase II compared the combination at the selected dose with dacarbazine alone. Keeping those questions separate is essential: the dose cohorts are not interchangeable with the randomized Phase II groups, and the Phase Ib DLT endpoint is not the same outcome as the Phase II progression-free survival endpoint.

The record also illustrates why endpoint definitions matter. A dose-limiting toxicity was not simply any adverse event; it was defined by timing, clinical significance, and the investigator’s assessment of possible or probable relation to treatment. These criteria govern which observations count toward the primary Phase Ib endpoint. Without the endpoint result and dose-selection details, readers can understand the method’s purpose but cannot evaluate its observed result.

Another statistical issue is the distinction between descriptive safety counts and comparative inference. The registry reports serious adverse event counts in each listed group, but counts alone do not provide a treatment-effect estimate or its precision. Small Phase Ib cohorts make descriptive comparisons especially difficult to interpret. The Phase II figures are more directly tied to the randomized comparison, yet the record does not report a comparative estimate, confidence interval, or analysis details.

Finally, the record makes clear that trial objectives and trial results are not equivalent. A planned preliminary efficacy assessment and a listed secondary outcome do not show what the data found. The absence of numerical DLT and progression-free survival results limits conclusions, and missing analysis-plan details limit evaluation of multiplicity, missing data, and population definitions. These distinctions are useful when reading any registry record: design describes intended evidence generation, whereas estimates and uncertainty are needed to interpret what the observed data support.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record does not report numerical results for the primary Phase Ib DLT endpoint. It also does not report the Phase II progression-free survival result, a comparative effect estimate, or confidence intervals. The maximum tolerated dose determination is not reported, so the Phase II combination dose cannot be linked to the Phase Ib toxicity pattern using the posted results alone.

The recorded total enrollment is 97, but the record does not state a sample-size justification or provide enough information to determine enrollment by phase beyond the listed safety groups. Allocation ratio and randomization procedures are not reported. The trial was open-label, and the record does not describe independent or masked outcome assessment. These details limit assessment of potential bias without establishing that bias occurred.

Analysis-population details are incomplete. A Phase Ib safety analysis set is defined, but equivalent definitions for the Phase II outcomes are not reported. The handling of missing outcomes, the number of participants with missing assessments, and sensitivity analyses are not reported. A detailed statistical analysis plan, multiplicity procedure, and interim-analysis information are also not reported in the registry record.

The serious adverse event counts are descriptive. The record does not provide uncertainty intervals or a comparative statistical analysis for them. The listed serious adverse event term percentages do not have a sufficiently clear group-specific denominator in the record to interpret them as treatment-specific risks. Deaths are not reported in the registry record. These limitations mean the available information can characterize parts of the design and safety reporting, but cannot support a complete statistical evaluation of efficacy or safety.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma — NCT01133977.
• Registry record last updated 2016-10-10; status last verified 2016-08.
• Results first posted 2016-10-10.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01133977 is recorded as a completed, randomized, open-label, multicenter, parallel Phase Ib/II study with an overall enrollment of 97 and a condition of stage IV melanoma. Phase Ib evaluated lenvatinib with dacarbazine at 16 mg, 20 mg or 22 mg once daily for safety, tolerability, and dose finding. Phase II compared lenvatinib at the Phase Ib maximum tolerated dose with dacarbazine against dacarbazine alone.

The listed primary endpoint was Phase Ib participants with a dose-limiting toxicity during the first cycle, defined using timing, clinical significance, and investigator-assessed relationship to treatment. Progression-free survival was a Phase II secondary outcome. The record posts serious adverse event counts by dose cohort and Phase II group, but does not report the numerical DLT result, the progression-free survival result, comparative estimates, or confidence intervals. Detailed information on sample-size justification, missing-data handling, multiplicity, and interim analyses is not reported in the registry record.